Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Psyence Biomedical ( (PBM) ) has issued an announcement.
Psyence BioMed has announced a strategic investment in PsyLabs, establishing operations in Africa to enhance its ibogaine production capabilities. This move positions the company uniquely within the psychedelics sector, allowing it to control the quality of ibogaine from its natural source to the finished product. The investment strengthens Psyence BioMed’s supply chain and positions it at the forefront of psychedelic drug development, with significant implications for stakeholders as global interest in ibogaine as a treatment for addiction and mental health disorders grows. The company’s presence in Africa offers a strategic advantage, providing early access to pipeline products and supporting its vertically integrated model as ibogaine moves into clinical and commercial phases.
More about Psyence Biomedical
Psyence Biomedical Ltd. is a biopharmaceutical company specializing in psychedelic-based therapeutics, focusing on nature-derived psilocybin and ibogaine for unmet mental health needs. It is the first life sciences biotechnology company in this field to be listed on Nasdaq, emphasizing an evidence-based approach to developing safe, effective, and FDA-approved treatments for mental health disorders.
Average Trading Volume: 902,266
Technical Sentiment Signal: Sell
Current Market Cap: $5.22M
For a thorough assessment of PBM stock, go to TipRanks’ Stock Analysis page.